Some biochemical aspects of the potential benefit of associating MD780515 with tricyclic antidepressants

Abstract

Abstract In the rat, suitable oral doses of tricyclic antidepressants (amitriptyline 20 mg kg−1, imipramine, desipramine 2·5 mg kg−1) are able to antagonize the increase of cardiac levels of intravenous tyramine after a pharmacologically active dose (3·5 mg kg−1 orally) of a reversible and specific type A MAO inhibitor, MD780515 (3-[4-(3-cyanophenyl-methoxy)phenyl]-5-(methoxymethyl)-2-oxazolidinone). MD780515, in oral doses up to 35 mg kg−1, does not alter the liver microsomal drug metabolizing enzymes in the rat. Therefore, when given with tricyclic antidepressants, it should not interfere with their metabolism.